# An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis

> **NCT03777436** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 289 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Apremilast
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03777436
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-11
- **Primary completion:** 2021-09-23
- **Final completion:** 2022-02-09
- **Target enrollment:** 289 (ACTUAL)
- **Last updated:** 2024-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03777436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03777436, "An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03777436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*